chevron_leftBack
As of 14 June 2026, Jeil Pharmaceutical Co.,Ltd has a market cap of $136.63M USD, ranking #23446 globally and #1031 in South Korea.
It ranks #2103 in the Healthcare sector, and #757 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$136.63MUSD
207.79B KRW
Enterprise Value
$185.96MUSD
282.33B KRW
Revenue (TTM)
$372.99MUSD
567.24B KRW
EBITDA (TTM)
$21.94MUSD
33.31B KRW
Net Income (TTM)
$15.38MUSD
23.38B KRW
EBITDA Margin
5.9%
Profit Margin
4.1%
PE Ratio
8.9
PS Ratio
0.4
PB Ratio
0.8
EV/EBITDA
8.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
947
Founded
1959
Website
jeilpharm.co.kr
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.7% | 2.9% | 0.3% | -3.7% | -2.3% | 17% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
271980
제일약품(주)
ISIN: KR7271980005
Shares Out.:
Shares Outstanding:
14.705M1
Shares Float:
5.387M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
13,880 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Jeil Pharmaceutical Co.,Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.15B
7K%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.77B
5K%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.24B
4K%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.96B
4K%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.55B
3K%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.44B
3K%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
557K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
400K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
264K%
|
97.4
|
|
SIX: RO
|
$321.52B
235K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
211K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
201K%
218.9B CHF
|
20.5
|
chevron_leftBack